文献速递临床试验与 GCP

藿香正气治疗腹泻型肠易激综合征的双盲随机对照试验方案

The Chinese herbal formula Huoxiang Zhengqi for diarrhea-predominant irritable bowel syndrome (CHAIRS): a study protocol for a double-blinded randomized controlled trial.
PubMed 文献 · Trials · 2021-07-26

本研究为双盲、随机、安慰剂对照试验,计划纳入212例腹泻型肠易激综合征(IBS-D)患者,按1:1随机接受藿香正气口服液或安慰剂治疗4周并随访4周,主要结局为充分缓解,旨在评估藿香正气的疗效与安全性。

要点

  • 藿香正气口服液治疗IBS-D的疗效与安全性尚需高级别证据验证。
  • 试验采用双盲、随机、安慰剂对照设计,计划纳入212例IBS-D患者。
  • 主要结局为充分缓解,次要结局包括IBS症状严重程度和生活质量等。

核心结论

  • 本试验旨在验证藿香正气口服液对IBS-D的疗效与安全性,预期其成为有效治疗选择。

研究设计与样本

  • 双盲、随机、安慰剂对照试验,计划纳入212例符合条件的IBS-D患者,按1:1随机分组。
  • 治疗4周,随访4周;试验注册于中国临床试验注册中心(ChiCTR1900026837)。

关键数值与推荐

  • 主要结局指标为充分缓解(adequate relief)。
  • 次要结局指标包括IBS症状严重程度评分、IBS生活质量问卷、EQ-5D-5L和中医症状问卷。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diarrhea-predominant irritable bowel syndrome (IBS-D) is a common chronic digestive disease. Recent observational studies have reported that the Chinese herbal formula Huoxiang Zhengqi (HXZQ) can relieve IBS-D symptoms, but no high-level evidence is presented. Therefore, we want to evaluate the efficacy and safety of HXZQ for IBS-D patients. METHODS: This is a double-blind, randomized, placebo-controlled trial. The 212 eligible patients with IBS-D will be randomly assigned to receive either HXZQ oral liquid or a placebo, at a 1:1 ratio, for 4 weeks with a 4-week follow-up period. Adequate relief will be the primary outcome measures. IBS symptom severity score, IBS quality-of-life questionnaire, EQ-5D-5L, and Chinese medicine symptom questionnaire will be the secondary outcome measures. DISCUSSION: This trial aims to demonstrate the efficacy and safety of HXZQ for IBS-D, which is expected to be an effective IBS-D treatment. TRIAL REGISTRATION: The trial was registered with the Chinese Clinical Trial Registry, ChiCTR1900026837 . Registered on 24 October 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Guo X, Xuan M, Zheng H, et al. The Chinese herbal formula Huoxiang Zhengqi for diarrhea-predominant irritable bowel syndrome (CHAIRS): a study protocol for a double-blinded randomized controlled trial. Trials. 2021. PMID: 34311755. doi:10.1186/s13063-021-05444-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。